

# **Abstract**



## **Main text**



 We quantified antibodies reactive to group 1 HA stalks (H1 and H5) and group 2 HA stalks (H3 and H7) in serum samples collected in 2017 from 121 healthy adults born

 between 1927-1998 (19-90 years old at time of sampling). H1 and H5 stalk-reactive antibodies were higher in older adults, although younger adults possessed moderate amounts of these antibodies (**Fig. 1b-c**). We asked if stalk-reactive antibody levels correlated with the probability of immune imprinting (i.e., initial infection in childhood) with viruses of the same subtype or group, estimated from historical data. H1 and H5 stalk-reactive antibody titers were both positively correlated with group 1 and H1N1 imprinting probabilities (**Table S1**). We found that group 2 HA stalk antibody levels were generally lower with no obvious correlation between titer and birth year (**Fig. 1d-e, Table S1**). H3 stalk-reactive antibodies were present in sera at similar levels regardless of donor age (**Fig. 1d**) and H7 stalk-reactive antibodies were generally low in the sera from most donors (**Fig. 1e**).

 Consistent with the group 1 HA stalk titer data, we found that individuals imprinted with group 1 viruses in childhood possessed high levels of antibodies reactive to clade 1 H5 full length HA (A/Vietnam/1203/2004) (**Fig. 1f**, **Table S1**) and clade 2.3.4.4b H5 full length HAs (A/Pheasant/New York/22-00906-001/2022 and A/Dairy Cattle/Texas/24-008749-002-v/2024) (**Fig. 1g**, **Extended Data Fig. 2**, and **Table S1**). Most of these cross-reactive antibodies were non-neutralizing, although we detected antibodies that neutralized clade 1 and clade 2.3.4.4b H5N1 in rare individuals of all ages (**Extended Data Fig. 3**). Taken together, our data suggest that childhood exposures to H1N1 and H2N2 prime mostly non-neutralizing group 1 HA stalk antibodies 94 that bind to diverse H5 HAs. Previous studies showed that H5 vaccines elicit HA stalk antibodies in

96 bumans<sup>22,23</sup>; however, it is unknown if H5 vaccines elicit different levels of HA stalk antibodies in individuals with different birth years. We obtained serum samples collected from children and adults (born between 1918-2003) before and after administration of a 45 µg dose of an H5N1 (A/Vietnam/1203/2004) unadjuvanted vaccine (ClinicalTrials.gov

 $#s$ : NCT00133536, NCT00230750, NCT00115986 $^{24}$ ). Since these clinical studies were completed in the years 2005-2006, the participants ranged from 2-97 years of age at time of vaccination. All participants received a prime-boost regiment, and we analyzed 103 serum samples before vaccination and 28 days after the  $1<sup>st</sup>$  and  $2<sup>nd</sup>$  vaccination. Consistent with our previous results, older adults possessed high levels of H5 stalk- reactive antibodies before vaccination (**Fig. 2a**). H5 stalk-reactive antibody levels increased slightly in older individuals and more substantially in children after each vaccination (**Fig. 2b-c**). We observed the highest fold change in H5 stalk-reactive antibody titers in children, whose antibody levels were lower prior to vaccination (**Fig. 2d**). We obtained similar data when we measured antibodies reactive to the full length A/Vietnam/1203/2004 HA vaccine antigen (**Fig. 2e-h**). Older individuals possessed higher levels of A/Vietnam/1203/2004 HA-reactive antibodies relative to children before vaccination (**Fig. 2e**) and these antibodies were boosted in participants in all age groups after vaccination (**Fig. 2f-g**) with the greatest benefit in children (**Fig. 2h**). Consistent 114 with a recent report<sup>25</sup>, we found that the clade 1 A/Vietnam/1203/2004 H5N1 vaccine elicited antibodies that bound to the more recent antigenically distinct clade 2.3.4.4b HA (**Fig. 2i-l**). Antibody levels against the clade 1 and clade 2.3.4.4b HAs were similar after vaccination (compare **Fig. 2g** and **Fig. 2k**). While some HA stalk antibodies are broadly neutralizing, many of these antibodies protect through Fc receptor-dependent mechanisms such as antibody 120 dependent cellular cytotoxicity (ADCC)<sup>26</sup>. We therefore determined if antibodies elicited by the A/Vietnam1203/2004 vaccine neutralized H5 virus or mediated ADCC with matched and mismatched H5 HAs. The vaccine elicited antibodies that neutralized clade

1 virus (**Extended Data Fig. 4a-c**) with larger fold-change titer increases in children

- (**Extended Data Fig. 4d**). The clade 1 vaccine antigen also elicited clade 2.3.4.4b
- neutralizing antibodies in some participants, but this was more sporadic (**Extended Data**

 **Fig. 4e-h**). ADCC activity against the clade 1 and clade 2.3.4.4b H5N1 viruses was high in serum from older individuals prior to vaccination (**Extended Data Fig. 4i and 4m**) and increased in younger individuals following vaccination (**Extended Data Fig. 4j-k and 4n- o**), with the largest ADCC titer fold change in children following vaccination (**Extended Data Fig. 4l and 4p**).

 Finally, we directly compared antibody titers from our healthy donors (**Fig. 1**) with pre-vaccination titers from adults from the H5 vaccine trials (**Fig. 2**). Since these samples were collected 12 years apart (2005 versus 2017), we were able to determine if H5 antibody levels were more closely associated with birth year or age (**Fig. 3a-b**). Consistent with immune imprinting, antibody levels were similar across these datasets when plotted as a function of birth year (**Fig. 3a**) but different when plotted as a function of age (**Fig. 3b**). Using two different statistical approaches, we found that titers to full length H5 proteins from clade 1 and clade 2.3.4.4b (but not to the H5 stalk) had stronger statistical associations with year of birth and group 1 imprinting probability than with age (**Tables S2** and **S3**). Antibody levels were less strongly associated with H1N1 imprinting 141 than with group 1 imprinting, suggesting that initial infections with H1N1 or H2N2 prime antibody responses against clade 1 and clade 2.3.4.4b H5 proteins. Taken together, these analyses corroborate the role of imprinting with group 1 viruses in shaping antibody levels to H5N1 in humans.

 Further studies need to be completed to determine if strong immunological imprinting is solely a byproduct of initial influenza virus encounters or if multiple exposures during childhood are required to prime robust memory B cell responses. Our previous studies suggest that heterosubtypic influenza virus infections in ferrets and 149 humans boost HA stalk responses against the originally infecting viral subtype<sup>27</sup>. Longitudinal cohort studies, in which infections and vaccinations are tracked carefully from birth, are required to better understand how childhood exposures impact the

generation of influenza virus antibodies later in life. In our experiments, younger

individuals possessed lower levels of H5-reactive antibodies prior to vaccination, and it is

likely that many of the younger children in our study had not yet been exposed to group

1 viruses at the time of sample collection.

Our study has limitations. For our vaccination studies, we analyzed serum

samples from 3 separate clinical studies to compare antibody responses elicited in

individuals with diverse birth years. The same vaccine formulation, dose, and

vaccination schedule were used in all 3 clinical studies, so it is unlikely that the observed

differences were due to clinical study differences. We only compared antibody

responses elicited by unadjuvanted vaccines in our studies. Khurana and colleagues

recently reported that adjuvanted clade 1 H5N1 vaccines elicit antibodies with high

163 reactivity to clade 2.3.4.4b H5N1 viruses<sup>25</sup>, and it will be important for future studies to

evaluate if there are birth year-related differences in responses to adjuvanted vaccines.

We only evaluated antibody responses to HA, and additional studies should be

completed to determine if humans possess cross-reactive antibodies against the

neuraminidase protein of H5N1. Finally, all our vaccine studies were based on clade 1

H5N1 antigens, and future studies should evaluate responses to other vaccine antigens

based on more contemporary H5N1 strains.

 Based on our studies and the observation that H5N1 viruses have typically 171 caused more disease in younger individuals<sup>15,16</sup>, it is possible that older individuals would be partially protected in the event of an H5N1 pandemic. Younger individuals who have fewer group 1 influenza virus exposures would likely benefit more from an H5N1 174 vaccine, even a mismatch stockpiled vaccine<sup>28</sup>. It will be important to continue to test new updated vaccine antigens in individuals with diverse birth years, including children. It will also be important to closely monitor clade 2.3.4.4b H5N1 virus circulating in wild

- and domestic animals, as well as spillover infections of humans, so that we can continue 178 to evaluate the pandemic risk of these viruses.
- 

### **Acknowledgments**

- We thank the Penn Medicine BioBank as a resource for obtaining serum from humans
- with different birth years. We thank NIAID and the VTEU clinical study teams from DMID
- 04-063, DMID 04-076, and DMID04-0077 for providing sera samples from clinical
- studies. This project was funded in part with Federal funds from the National Institute of
- Allergy and Infectious Diseases, National Institutes of Health, Department of Health and
- Human Services, under Contract Nos. 75N93021C00015 (S.E.H. and S.C.) and grant
- numbers R01AI08686 (S.E.H.). S.E.H. holds an Investigators in the Pathogenesis of
- Infectious Disease Awards from the Burroughs Wellcome Fund.
- 

# **Author Contributions Statement**

S.E.H., T.A.G., J.L., S.H.L., G.S., C.F., and J.J.S.S. designed the experiments. T.A.G.,

J.L., S.H.L., G.S., J.J.S.S., G.H., C.F., R.K.A., N.Y., J.O., K.A.H., and T.E. completed

experiments and analyzed data. K.K., M.C.V., and S.Co. performed modeling studies.

S.E.H. wrote the manuscript and all authors contributed to editing the manuscript. D.S.,

 S.Ch., S.Co., and S.E.H. supervised experiments and data analyses. S.E.H. obtained funding for the study.

### **Competing Interests Statement**

 S.E.H. is a co-inventor on patents that describe the use of nucleoside-modified mRNA as a vaccine platform. S.E.H reports receiving consulting fees from Sanofi, Pfizer, Lumen, Novavax, and Merck. T.A.G. was an employee of the University of Pennsylvania when the

work was completed and is now an employee of GSK. The authors declare no other

competing interests.



replicates. Samples from adults are grey and children are blue. Trend lines are locally

- estimated scatterplot smoothing (LOESS) curves (smoothing parameter = 0.4, degree =
- 2) with 95% confidence intervals, fitted to adult samples.
- 

# **Fig. 3. H5-rective antibody levels correlate better with birth year compared to age**.

- Antibody titers in samples collected in 2005 (yellow) and 2017 (blue) against H5 stalk,
- clade 1 A/Vietnam/1203/2004 full length H5, and clade 2.3.4.4b A/Pheasant/New
- York/22-009066-011/2022 full length H5 are shown as a function of birth year (**a**) and
- age (**b**). Vertical dashed lines mark years of the 1957 H2N2 and 1968 H3N2 pandemics
- and 1977 reemergence of H1N1 (**a**). Each circle represents a geometric mean antibody
- 239 titer in serum from a single donor from two independent replicates. Trend lines are
- 240 locally estimated scatterplot smoothing (LOESS) curves (smoothing parameter = 0.65,
- degree = 2) with 95% confidence intervals, fitted to adult samples.
- 
- 
- 

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.10.31.24316514;](https://doi.org/10.1101/2024.10.31.24316514) this version posted November 2, 2024. The copyright holder for this preprint

### **References**

- 1. Lewis, N.S.*, et al.* Emergence and spread of novel H5N8, H5N5 and H5N1 clade 2.3.4.4 highly pathogenic avian influenza in 2020. *Emerging Microbes & Infections* **10**, 148-151 (2021).
- 2. Caliendo, V.*, et al.* Transatlantic spread of highly pathogenic avian influenza H5N1 by wild birds from Europe to North America in 2021. *Sci Rep* **12**, 11729 (2022).
- 3. King, J.*, et al.* Highly pathogenic avian influenza virus incursions of subtype H5N8, H5N5, H5N1, H5N4, and H5N3 in Germany during 2020-21. *Virus Evolution* **8**(2022).
- 4. Adlhoch, C.*, et al.* Avian influenza overview December 2022 March 2023. *Efsa j* **21**, e07917 (2023).
- 5. Rijks, J.M., et al. Highly Pathogenic Avian Influenza A(H5N1) Virus in Wild Red Foxes, the Netherlands, 2021. *Emerg Infect Dis* **27**, 2960-2962 (2021).
- 6. Puryear, W.*, et al.* Outbreak of Highly Pathogenic Avian Influenza H5N1 in New England Seals. *bioRxiv*, 2022.2007.2029.501155 (2022).
- 7. Pyankova, O.G.*, et al.* Isolation of clade 2.3.4.4b A(H5N8), a highly pathogenic avian influenza virus, from a worker during an outbreak on a poultry farm, Russia, December 2020. *Euro Surveill* **26**(2021).
- 8. Agüero, M.*, et al.* Highly pathogenic avian influenza A(H5N1) virus infection in farmed minks, Spain, October 2022. *Euro Surveill* **28**(2023).
- 9. Nguyen, T.Q., Hutter, C., Markin, A., Thomas, M., Lantz, K., Killian, M.L., Janzen, G.M., Vijendran, S., Wagle, S., Inderski, B., Magstadt, D.R., Li, G., Diel, D.G., Frye, E.A., Dmitrov, K.M., Swinford, A.K., Thompson, A.C., Snevik, K.R., Suarez, D.L., Spackman, E., Lakin, S.M., Ahola, S.C., Johnson, K.R., Baker, A.L., Robbe-Austerman, S., Torchetti, M.K., Anderson, T.K. Emergence and interstate spread
- of highly pathogenic avian influenza A(H5N1) in dairy cattle. *bioRxiv* **https://doi.org/10.1101/2024.05.01.591751**(2024). 10. Burrough, E.R.*, et al.* Highly Pathogenic Avian Influenza A(H5N1) Clade 2.3.4.4b
- Virus Infection in Domestic Dairy Cattle and Cats, United States, 2024. *Emerg Infect Dis* **30**, 1335-1343 (2024).
- 11. Santos, J.J.S.*, et al.* Bovine H5N1 influenza virus binds poorly to human-type sialic acid receptors. *bioRxiv* (2024).
- 12. Chopra, P.*, et al.* Receptor Binding Specificity of a Bovine A(H5N1) Influenza Virus. *bioRxiv* (2024).
- 13. Neumann, G. & Kawaoka, Y. Highly pathogenic H5N1 avian influenza virus outbreak in cattle: the knowns and unknowns. *Nat Rev Microbiol* **22**, 525-526 (2024).
- 14. Moratorio, G.*, et al.* H5N1 influenza: Urgent questions and directions. *Cell* **187**, 4546-4548 (2024).
- 15. Qin, Y.*, et al.* Differences in the Epidemiology of Human Cases of Avian Influenza A(H7N9) and A(H5N1) Viruses Infection. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* **61**, 563-571 (2015).
- 16. Cowling, B.J.*, et al.* Comparative epidemiology of human infections with avian influenza A H7N9 and H5N1 viruses in China: a population-based study of laboratory-confirmed cases. *Lancet* **382**, 129-137 (2013).
- 17. Krammer, F.*, et al.* Influenza. *Nat Rev Dis Primers* **4**, 3 (2018).









**Fig. 3**





